EZR and cervical cancer: For early-stage (I–IIA) cervical cancer patients, the survival analysis demonstrated that high ezrin expression was associated with lower 10-year survival rate (log-rank P=0.030; Figure 4), but there was no significance in patients with advanced stage (IIB–IV) cervical cancers (data not shown, log-rank P=0.352).